Johnson and Johnson

10.11.2026 г., 23:01 ч. UTC

Johnson & Johnson's Study 452 for CAPLYTA successfully met its primary and key secondary endpoints in treating manic episodes in bipolar I disorder.

9.11.2026 г., 21:04 ч. UTC

Johnson & Johnson announced positive Phase 3 data for ICOTYDE, showing 58% of psoriatic arthritis patients achieved an ACR20 response at Week 16.

7.11.2026 г., 00:02 ч. UTC

Johnson & Johnson shares are trading lower in after-market hours, having pulled back from a brief peak shortly after the market closed.

6.11.2026 г., 23:02 ч. UTC

Johnson & Johnson shares declined in after-market trading, pulling back from a brief peak, indicating unusual weakness today.

5.11.2026 г., 23:41 ч. UTC

Johnson & Johnson shares are lower in after-market trading.

4.11.2026 г., 23:02 ч. UTC

Johnson & Johnson shares are modestly lower in after-market trading, having declined from a brief uptick earlier in the session.

3.11.2026 г., 23:06 ч. UTC

Johnson & Johnson shares declined in after-market trading, reversing earlier gains, and marking five consecutive sessions of lower closes.

2.11.2026 г., 23:02 ч. UTC

Johnson & Johnson's shares advanced modestly in after-market trading, following notable fluctuations during the session while remaining above its 20-day moving average.

30.10.2026 г., 23:06 ч. UTC

Johnson & Johnson shares are trading slightly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

29.10.2026 г., 23:01 ч. UTC

Johnson & Johnson shares advanced during after-market hours, reflecting a broader upward movement in the Pharmaceuticals sub-sector amid recent higher daily closes.

28.10.2026 г., 23:02 ч. UTC

Johnson & Johnson shares advanced in after-market trading, supported by gains in the Pharmaceuticals sub-sector, and remain significantly above their 20-day moving average.

27.10.2026 г., 23:01 ч. UTC

Johnson & Johnson shares are modestly lower in after-market trading, having shifted from a slight gain to a more significant loss today.

26.10.2026 г., 20:07 ч. UTC

Johnson & Johnson reported positive clinical data at the European Society for Medical Oncology Congress 2026, showing strong response rates for its investigational drug JNJ-6143.

23.10.2026 г., 19:56 ч. UTC

Johnson & Johnson is under investigation by Bronstein, Gewirtz & Grossman, LLC, after a significant decline in net earnings and disappointing MedTech sales.

22.10.2026 г., 23:51 ч. UTC

Johnson & Johnson shares traded modestly lower during after-market hours on Thursday, breaking a recent trend of higher daily closes.

21.10.2026 г., 23:06 ч. UTC

Johnson & Johnson shares advanced in after-market trading, reflecting a modest increase since Wednesday's close and currently positioned in the middle of its one-month range.

20.10.2026 г., 22:51 ч. UTC

Johnson & Johnson's shares are trading modestly lower in after-market hours, amid broader weakness in the Pharmaceuticals sub-sector, reaching the day's lowest point.

19.10.2026 г., 20:07 ч. UTC

Johnson & Johnson reported positive Phase 3 FUZION study results for TREMFYA, showing improved fistula remission in Crohn's disease patients over 48 weeks.

16.10.2026 г., 23:01 ч. UTC

Johnson & Johnson shares are trading modestly lower in after-market hours, having reached their lowest cumulative return of the day.

15.10.2026 г., 23:06 ч. UTC

Johnson & Johnson reported Q3 sales of $25.4 billion and raised its full-year sales growth guidance to approximately 7%, with shares flat in after-market hours.

14.10.2026 г., 23:41 ч. UTC

Johnson & Johnson shares advanced in after-market trading, recovering from a low shortly after the market closed and reaching a notable high by late in the session.

13.10.2026 г., 23:01 ч. UTC

Johnson & Johnson shares advanced modestly in after-market trading, recovering from a low shortly after Tuesday's close, but remain below their 20-day moving average.

12.10.2026 г., 20:07 ч. UTC

Q3 earnings announcement on October 13; EPS forecast at $2.52.

9.10.2026 г., 23:50 ч. UTC

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEADa study for ICOTYDE® in treating moderate-to-severe plaque psoriasis.

8.10.2026 г., 23:05 ч. UTC

Johnson & Johnson shares declined in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

7.10.2026 г., 20:01 ч. UTC

Guggenheim reiterated its Buy rating on Johnson & Johnson with a $287 price target as the stock advances, having gained momentum since Tuesday's close.

6.10.2026 г., 20:07 ч. UTC

RBC Capital maintained its Outperform rating on Johnson & Johnson and raised its price target to $290, contributing to a modest increase in shares today.

5.10.2026 г., 19:52 ч. UTC

Johnson & Johnson shares fell sharply despite Citi raising its price target to $303 ahead of next week's earnings report, continuing a trend of lower performance.

2.10.2026 г., 20:07 ч. UTC

Johnson & Johnson shares declined as the company presented positive data from its ICONIC-TOTAL study, showing 70% of patients achieved clear skin at Week 112.

1.10.2026 г., 23:05 ч. UTC

Johnson & Johnson is trading slightly higher in after-market hours, recovering from three consecutive lower daily closes, though still below its 20-day moving average.